We have also demonstrated the therapeutic potential of anti-IL-1 approaches for treating acute injury to the brain [7–9]; however, a limitation of such an approach is the potential for increasing vulnerability to infection through systemic suppression of innate immunity. This evidence concerns the gene IL1A and infection.